Two New Triterpenoid Glycosides Isolated from *Aesculus assamica* GRIFF

Hongwei LIU,^{*,a} Xue ZHANG,^b Hao GAO,^b Nali WANG,^{b,d} Sanlin JIN,^b Bin CAI,^c Xinsheng YAO,^{*,b,d} and Guoping CAI^a

^aLife Science Division, Graduate School at Shenzhen, Tsinghua University; The University Town, Shenzhen 518055, People's Republic of China; ^bShenzhen Research Center of Traditional Chinese Medicine and Natural Products; The University Town, Shenzhen 518055, People's Republic of China; ^cLaboratory of Bioactive Assay, Tianjin Institute of Biomedicine; Tianjin 300384, People's Republic of China; and ^dDepartment of Natural Product Chemistry, Shenyang Pharmaceutical University; Wenhua-Road 103, Shenyang 110016, People's Republic of China.

Received January 17, 2005; accepted June 13, 2005

Phytochemical study of the ethanol extract of the seeds of *Aesculus assamica* led to the isolation of two new triterpenoid saponins. The structure of the new compounds were elucidated on the basis of spectral data to be 28-*O*-acetyl-21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopyranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin (1), and 21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopyranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin (2). Their *in vitro* bioactivity against plant pathogenic fungus *Pyricularia oryzae* and cytotoxicity against K562 and HCT-15 cell lines were evaluated.

Key words triterpenoid glycoside; *Aesculus assamica*; anti-fungal activity; cytotoxicity

The plants of *Aesculus* genus (Family Hippocastanaceae) have attracted much interests of phytochemists for many years due to the discovery of acylated triterpenoid saponins-escins with extraordinary anti-inflammatory activity from horse chestnut (*Aesculus hippocastanum* L.) seeds and the successful applications of its seeds extract for treatment of peripheral chronic venous insufficiency or as ingredients in cosmetics. The *Aesculus* genus consists of about thirty species distributed in Asia, Europe and America. There are sixteen species distributed in China, and most of them are used as herbal medicines for the treatment of distention and pain in the chest and abdomen. A number of escins-like saponins have been isolated from plants of this genus,^{1–11)} and of which various biological activities have been studied and reported, such as anti-inflammatory, hypoglycemic activities, inhibitory effects on ethanol absorption, as well as anti-HIV-1 protease activities. During our search for a substitute in China, we did phytochemical investigation on the seeds of *A. assamica* GRIFF, a plant distributed in Yunnan Province of China. Two novel triterpenoid saponins with insulin-like activity, termed assamicins I and II, have been isolated from *A. assamica*.¹²⁾ Herein, we describe the isolation, structure determination, and bioactivities of two new triterpenoid saponins, designated as assamicin III and IV.

Results and Discussion

The 95% EtOH extracts of *A. assamica* were separated as described in Experimental to yield compounds **1** and **2**, 28-*O*-acetyl-21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopyranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin (**1**) and 21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopyranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin (**2**) (Fig. 1).

Compound **1** was isolated as a white amorphous powder. Its IR spectrum showed absorption bands due to hydroxyl, carboxyl, ester, and olefin functions at 3409, 1724, 1720, 1678, 1654 and 1648 cm⁻¹, and two broad absorption bands at 3409 and 1049 cm⁻¹ suggested the possible existence of a

glycosidic structure. High resolution FAB-MS revealed the molecular formula of **1** to be C₆₁H₉₆O₂₈. In the positive ESI-MS of **1**, quasimolecular ion peak was observed at *m/z* 1299 [M+Na]⁺. The positive-ion ESI-MS²) spectrum of *m/z* 1299 gave ions at *m/z* 1137 [M+Na-162]⁺, 1077 [M+Na-60-162]⁺, 915 [M+Na-60-162-162]⁺, 739 [M+Na-60-162-162-176]⁺, 511 [M+Na-60-162-162-176-228]⁺, indicating the sequential losses of hexose units. The ¹H- and ¹³C-NMR signals of **1** showed a close resemblance to those of isoescins Ib that contains trisaccharide moiety attached at the C-3 of protoaescigenin skeleton.⁸⁾ Alkaline hydrolysis of **1** with 10% aqueous potassium hydroxide in 50% aqueous dioxane (1 : 1) produced the deacylated saponin that was purified by silica gel preparative TLC. The amount of deacylated saponin obtained was too little to get the good NMR data, it was only analyzed by ESI-MS/MS spectrum (1157 [M+Na]⁺, 995 [M+Na-162]⁺, 833 [M+Na-162-162]⁺, 657 [M+Na-162-162-176]⁺, 511 [M+Na-162-162-176-146]⁺). The further acid hydrolysis of the deacylated saponin liberated aglycone and sugars. 6-Deoxy-glucose, glucose and glucuronic acid were identified by paper chromatography and GC in comparison with authentic, and a mixture of sapogenins including protoaescigenin were detected by TLC comparison with authentic.^{8,11)} The ¹H- and ¹³C-NMR signals were assigned by a combination of DEPT, COSY, TOSCY, HMQC, HMBC, and NOESY spectra, which included signals due to the protoaescigenin skeleton [¹H-NMR: 0.63 (Me-25), 0.71 (Me-26), 1.24 (Me-23), 1.48 (Me-29), 1.30 (Me-30) and a broad signal at 5.38 (H-12)], four sugar moieties [¹H-NMR: β -anomeric protons at 4.85 (d, *J*=7.6 Hz, H-1'), 5.53 (d, *J*=7.6 Hz, H-1''), 5.18 (d, *J*=7.2 Hz, H-1'''), and 4.90 (d, *J*=7.6 Hz, H-1'''''); ¹³C-NMR: anomeric carbons at 104.7 (C-1'), 104.5 (C-1''), 104.6 (C-1'''), and 105.9 (C-1'''')], an acetyl group [¹H-NMR: 2.32 (s, 3H, acetyl-28), ¹³C-NMR: 169.4 (C=O-28)], and an angeloyl group [¹H-NMR: 1.92 (d, 3H, *J*=1.6 Hz, Me-3'''), 1.99 (dd, 3H, *J*=1.6, 7.2 Hz, Me-5'''), 5.94 (m, H-4'''); ¹³C-NMR: 128.3 (C-2'''), 137.8 (C-4'''), 167.4 (C=O-1''')]. The larger coupling constant for H-4''' at 5.32 (t, *J*=9.6 Hz) to-

* To whom correspondence should be addressed. e-mail: liuhongwei60@hotmail.com

Fig. 1. Structures of Compounds **1** and **2** Fig. 2. Key HMBC Correlations of Compound **1**

gether with HMBC correlation observed between CH₃-6''' and C-4''' indicated the presence of 6-deoxy- β -glucose, which was also confirmed by comparison with NMR data of assamicin II.¹²⁾ The position of sugar moiety at C-3 and C-21 and interlinking among sugar moiety were deduced from HMBC experiments, in which H-1', H-1'', H-1''', and H-1'''' were correlated with C-3 (90.8), C-2' (78.4), C-4' (82.0), and C-21 (90.8). The position of acetyl and angeloyl groups at C-28 and C-4''' were also deduced from HMBC spectrum as indicated in Fig. 2. The relative stereochemistry of **1** was confirmed to be the same as that of assamicin I and II by NOESY experiment. In its NOESY spectrum, Me-29 showed a strong correlation with H-21, while Me-30 correlated strongly with H-22 at 4.60 (d, $J=9.6$ Hz). These indicated the α configuration of H-21 and β configuration of H-22. The coupling constant of H-21 and H-22 ($J=10.0$ Hz) also supported the proposed structure. On the basis of the above evidence, the structure of compound **1** was determined to be 28-*O*-acetyl-21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopyranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin, and designated as assamicin III.

Compound **2** was isolated as amorphous powder. The molecular formula, C₅₉H₉₄O₂₇, was determined on the basis of the HR-FAB-MS spectrum. In the positive ESI-MS of **1**, qua-

simolecular ion peak was observed at m/z 1257 [M+Na]⁺. The positive-ion ESI-MS²) spectrum of m/z 1257 gave ions at m/z 1095 [M+Na-162]⁺, 933 [M+Na-162-162]⁺, 757 [M+Na-162-162-176]⁺, 529 [M+Na-162-162-176-228]⁺, indicating the sequential losses of hexose units. The IR, ¹H- and ¹³C-NMR spectrum of **2** showed very similarity to that of **1**, except for the loss of acetyl group at C-28. In summary, the characteristic signals of protoaescigenin skeleton including five methyl groups at δ [0.66 (Me-25), 0.82 (Me-26), 1.24 (Me-23), 1.51 (Me-29), 1.35 (Me-30) and a broad signal at δ 5.37 (H-12)], four anomeric protons of sugar moieties at δ [4.88 (d, $J=8.0$ Hz, H-1'), 5.51 (d, $J=7.6$ Hz, H-1''), 5.18 (d, $J=7.6$ Hz, H-1'''), and 4.86 (d, $J=8.0$ Hz, H-1''')], and an angeloyl signals at δ [1.89 (d, 3H, $J=1.6$ Hz, Me-3'''), 1.99 (dd, 3H, $J=1.6, 7.2$ Hz, Me-5'''), and 5.93 (dq, $J=1.6, 7.2$ Hz, H-4''')] were observed in its ¹H-NMR spectrum, and so was their corresponding carbon signals in the ¹³C-NMR spectrum of **2**. The whole structure of **2** was established from HMBC analysis, and signal assignments were accomplished in combination of COSY, TOCSY, HMQC, HMBC and NOESY spectral analysis. Compound **2** possess the same stereochemistry as that of **1**, which can be deduced from NOESY experiments. Based on the above analysis and comparison with the NMR data of **1**, compound **2** was identified as 21-*O*-(4-*O*-angeloyl)-6-deoxy- β -glucopy-

Table 1. ^{13}C -NMR Data of Compounds **1** and **2** (ppm, 100 MHz in $\text{C}_5\text{D}_5\text{N}$)

No.	1	2	No.	1	2
1	38.3	38.5	1'	104.7	104.7
2	26.4	26.5	2'	78.4	78.5
3	90.8	90.8	3'	76.8	76.8
4	43.7	43.8	4'	82.0	81.9
5	55.9	56.0	5'	76.2	76.2
6	18.4	18.5	6'	172.5	172.5
7	33.0	33.1	1''	104.5	104.5
8	39.8	39.9	2''	73.5	73.3
9	46.7	46.8	3''	78.4	78.4
10	36.2	36.3	4''	70.9	70.9
11	23.9	24.0	5''	78.0	78.0
12	122.9	122.9	6''	62.2	62.2
13	141.8	143.7	1'''	104.6	104.6
14	41.2	41.8	2'''	74.8	74.8
15	31.0	34.5	3'''	78.4	78.4
16	71.9	67.9	4'''	71.4	71.4
17	46.9	47.8	5'''	78.4	78.4
18	39.2	40.3	6'''	62.3	62.3
19	47.8	48.1	1''''	105.9	106.0
20	37.0	37.1	2''''	75.3	75.3
21	90.8	92.0	3''''	75.6	75.8
22	70.9	73.4	4''''	76.3	76.3
23	22.4	22.5	5''''	70.7	70.4
24	63.3	63.4	6''''	17.8	18.0
25	15.5	15.6	1'''''	167.4	167.4
26	16.5	16.6	2'''''	128.3	128.3
27	26.9	27.4	3'''''	20.6	20.6
28	64.6	66.7	4'''''	137.8	137.7
29	29.9	29.9	5'''''	15.8	15.8
30	19.6	20.2	1''''''	169.4	
			2''''''	22.0	

ranosyl-3-*O*-[β -glucopyranosyl(1 $\rightarrow$ 2)-*O*-[β -glucopyranosyl(1 $\rightarrow$ 4)]- β -glucuronopyranosyl]protoaescigenin (**2**), and named as assamicin IV.

Compounds **1** and **2** exhibited moderate activity against the plant pathogenic fungus *Pyricularia oryzae* with the minimal morphological deformation concentration (MMDC) values of 100 and 120 μM , respectively. A weak cytotoxicity on K562 and HCT-15 cell lines for **1** and **2** was observed ($\text{IC}_{50} > 100 \mu\text{g/ml}$).

Experimental

General Experimental Procedure Melting points were determined on a Yanaco MP-S₃ micromelting point apparatus, and were uncorrected. Optical rotations were measured using a P-1020 digital polarimeter (JASCO corporation). FAB-MS and HR-MS were obtained using a JEOL JMS-DX302 spectrometer. ESI-MS was conducted using Bruker esquire 2000 mass spectrometer. IR spectra were recorded on SHIMADZU FT/IR-8400 spectrometer. ^1H - and ^{13}C -NMR, along with 2D NMR spectra were obtained on a Bruker AV-400 (400 MHz for ^1H , 100 MHz for ^{13}C) NMR spectrometer, using TMS as an internal standard. Chemical shifts were expressed in δ (ppm) and coupling constants (J) were reported in Hertz (Hz). GC was done on a HP-5890 SERIES II spectrometer, with a SE30 capillary column (12 m, 0.22 mm i.d.), hydrogen flame ionization detector (FID, 270 $^\circ$), the column temperature was 170–250 $^\circ\text{C}$ with the rate of 5 $^\circ\text{C}/\text{min}$, and the carrier gas was N_2 (30 ml/min). TLC was carried out on Silica gel 60F₂₅₄ and the spots were visualized by sprayed with 10% H_2SO_4 and heating. Diaion HP-20 (Mitsubishi Kasei) and ODS (Lobar, 40–63 μm , Merck) were used for column chromatography. Preparative HPLC was performed using an ODS column (C-18, 250 $\times$ 20 mm, SHIMADZU Pak; detector: RID). Minimum essential medium (MEM) was obtained from Gibco and fetal calf serum (FCS) from Tianjin Chuanyie Bio-engineering Co. (Tianjin, China).

Extraction and Isolation The powdered seeds (2.0 kg) were extracted three times with 70% EtOH under reflux for 2 h. After removal of the sol-

vent *in vacuo*, the extract (250 g) was further partitioned between H_2O and EtOAc to give H_2O -soluble and EtOAc-soluble fractions. The H_2O -soluble (180 g) fraction was subjected to HP-20 resin column chromatography and eluted successively with H_2O , 30% EtOH, 50% EtOH, 70% EtOH, 95% EtOH, and 100% acetone to afford 6 fractions. The second fraction (50% EtOH eluate, 10 g) was further separated by ODS column eluted with 30% MeOH, 50% MeOH, 70% MeOH, 100% MeOH to give 10 subfractions. The third subfraction (50% MeOH eluate, 0.1 g) containing the high polar triterpenoid saponins was purified by preparative HPLC [MeOH–0.1% TFA aqueous solution (65 : 35, v/v), flow rate, 30 ml/min] to yield **1** (5 mg) and **2** (6 mg). The other parts are undergoing further separation.

Assamicin III (1): Amorphous powder, $[\alpha]_{\text{D}}^{24} -47.8^\circ$ ($c=0.2$, pyridine). HR-FAB-MS m/z $[\text{M}+\text{Na}]^+$ 1299.5186 (Calcd for $\text{C}_{61}\text{H}_{96}\text{O}_{28}\text{Na}$: 1299.5165). Positive-ESI-MS (m/z): 1299 $[\text{M}+\text{Na}]^+$, 1071, 981, 799, 661. Negative-ESI-MS (m/z): 1275 $[\text{M}-\text{H}]^-$. IR (KBr) cm^{-1} : 3409, 2947, 1724, 1720, 1678, 1654, 1648, 1380, 1238, 1049. ^1H -NMR (pyridine- d_5) δ : 3.29 (1H, m, H-3), 5.38 (1H, brs, H-6), 5.93 (1H, m, H-16), 2.96 (2H, d, $J=10.8$ Hz, H-18), 4.17 (1H, m, H-21), 4.6 (1H, d, $J=9.6$ Hz, H-22), 1.24 (3H, s, H-23), 3.29 (1H, m, H-24), 4.22 (1H, m, H-24), 0.63 (3H, s, H-25), 0.71 (3H, s, Me-26), 1.48 (3H, s, Me-27), 3.60 (1H, d, $J=12.0$ Hz, H-28), 3.92 (1H, m, H-28), 1.48 (3H, s, H-29), 1.30 (3H, s, H-30), 4.85 (d, $J=7.6$ Hz, H-1'), 5.53 (d, $J=7.6$ Hz, H-1''), 5.18 (d, $J=7.2$ Hz, H-1'''), and 4.90 (d, $J=7.6$ Hz, H-1'''), 5.32 (t, $J=9.6$ Hz, H-4'''), 3.90 (dq, $J=6.0$, 9.6 Hz, H-5'''), 2.32 (s, 3H, acetyl-28), 1.92 (d, 3H, $J=1.6$ Hz, Me-3'''), 1.99 (dd, 3H, $J=1.6$, 7.2 Hz, Me-5'''), 5.94 (m, H-4''').

Assamicin IV (2): Amorphous powder, $[\alpha]_{\text{D}}^{24} -40.5^\circ$ ($c=0.2$, pyridine). HR-FAB-MS m/z $[\text{M}+\text{Na}]^+$ 1257.4568 (Calcd for $\text{C}_{60}\text{H}_{94}\text{O}_{27}\text{Na}$: 1257.4542). Positive-ESI-MS (m/z): 1257 $[\text{M}+\text{Na}]^+$, 1029, 933, 757, 640. Negative-ESI-MS (m/z): 1233 $[\text{M}-\text{H}]^-$. IR (KBr) cm^{-1} : 3409, 2947, 1724, 1678, 1654, 1648, 1380, 1045. ^1H -NMR (pyridine- d_5) δ : 3.33 (1H, m, H-3), 5.37 (1H, brs, H-6), 4.98 (1H, brs, H-16), 2.96 (2H, dd, $J=4.0$, 11.6 Hz, H-18), 4.79 (1H, d, $J=9.6$ Hz, H-21), 4.62 (1H, d, $J=9.6$ Hz, H-22), 1.24 (3H, s, H-23), 3.32 (1H, m, H-24), 4.22 (1H, m, H-24), 0.66 (3H, s, H-25), 0.82 (3H, s, Me-26), 1.83 (3H, s, Me-27), 3.67 (1H, d, $J=11.8$ Hz, H-28), 3.79 (1H, d, $J=11.8$ Hz, H-28), 1.51 (3H, s, H-29), 1.35 (3H, s, H-30), 4.88 (d, $J=8.0$ Hz, H-1'), 5.51 (d, $J=7.6$ Hz, H-1''), 5.18 (d, $J=7.6$ Hz, H-1'''), and 4.86 (d, $J=8.0$ Hz, H-1'''), 5.32 (t, $J=9.6$ Hz, H-4'''), 3.62 (dq, $J=6.0$, 9.6 Hz, H-5'''), 1.92 (d, 3H, $J=1.6$ Hz, Me-3'''), 1.99 (dd, 3H, $J=1.6$, 7.2 Hz, Me-5'''), 5.94 (m, H-4''').

Alkaline and Acid Hydrolysis of Saponins A solution of saponin (**1** and **2**, 4 mg each) in 10% aqueous KOH–50% aqueous dioxane (1 : 1, v/v, 2 ml) was stirred at 37 $^\circ\text{C}$ for 1 h. The reaction mixture was neutralized with 10% acetic acid. After removal of the solvent from the filtrate under reduced pressure, the residue was dissolved in H_2O (5 ml) and extracted with EtOAc : BuOH (1 : 1). The organic solvents were evaporated and purified by Preparative TLC on silica gel (CHCl_3 : MeOH : H_2O , 70 : 30 : 5) to give the deacylated saponin (about 1.5 mg) for **1** and **2**. The product was redissolved in H_2O (1 ml) and treated with 20% aqueous H_2SO_4 (1 ml). The mixture was heated under reflux for 4 h, and then neutralized with saturated NaHCO_3 and extracted three times with EtOAc. TLC (CHCl_3 : MeOH, 95 : 5, $R_f=0.35$) analysis showed the presence of protoaescigenin in both **1** and **2** by comparison with authentic protoaescigenin.

The water layer was then condensed and divided into two parts. One part was subjected to paper chromatography and GC analysis. Glucuronic acid ($R_f=0.06$), glucose ($R_f=0.19$), and 6-deoxy-glucose ($R_f=0.40$) were detected by paper chromatography [n -BuOH–EtOH– H_2O –con. $\text{NH}_3/\text{H}_2\text{O}$, 45 : 5 : 49 : 1]. For GC analysis, the residue was trimethylsilylated with hexamethyldisilazane and trimethylchlorosilane in a 2 : 1 ratio at room temperature.¹³ Two peaks corresponding to derivatives of 6-deoxy-glucose (t_R : 4.18 min) and glucose (t_R : 7.35 min) were detected consistent with the authentic samples of 6-deoxy- β -D-glucose and β -D-glucose prepared in the same manner.

The other part was treated according to Hulyalkar's method and showed the existence of glucuronic acid.^{14,15} The retention time was 10.51 min (2,3,5,6-tetra-trimethylsilyl- β -D-gulono-1,4-lactone). Both **1** and **2** gave the same sugars: β -glucuronic acid, β -glucose, and 6-deoxy- β -glucose.

Bioassay Antifungal assay against plant pathogenic fungus *Pyricularia oryzae* and the cytotoxicity assay on cultured K562 and HCT-15 cell lines were carried out as previously reported.^{16,17}

Acknowledgment We appreciate the kind help of Prof. Qishi Sun in Shenyang Pharmaceutical University for his collection and identification of the plant material.

References

- 1) Singh B., Agrawal P. K., Thakur R. S., *J. Nat. Prod.*, **50**, 781—783 (1987).
- 2) Yoshikawa M., Harada E., Murakami T., Matsuda H., Watariishi N., Yamahara J., Murakami N., Kitagawa I., *Chem. Pharm. Bull.*, **42**, 1357—1363 (1994).
- 3) Yoshikawa M., Murakami T., Matsuda H., Yamahara J., Murakami N., Kitagawa I., *Chem. Pharm. Bull.*, **44**, 1454—1464 (1996).
- 4) Matsuda H., Li Y., Murakami T., Ninomiya K., Yamahara J., Yoshikawa M., *Biol. Pharm. Bull.*, **20**, 1092—1095 (1997).
- 5) Yoshikawa M., Murakami T., Yamahara J., Matsuda H., *Chem. Pharm. Bull.*, **46**, 1764—1769 (1998).
- 6) Yang X. W., Zhao J., Cui Y. X., Liu X. H., Ma C. M., Hattori M., Zhang L. H., *J. Nat. Prod.*, **62**, 1510—1513 (1999).
- 7) Zhao J., Yang X. W., Cui Y. X., Liu X. H., Liu S. Y., Zhi H. Y., Chen J. R., Zhu F. B., Xue Y. L., Liu D. B., *Chin. Chem. Lett.*, **10**, 291—294 (1999).
- 8) Zhao J., Yang X. W., Hattori M., *Chinese Traditional and Herbal Drugs*, **31**, 648—651 (2000).
- 9) Zhao J., Yang X. W., Hattori M., *Chem. Pharm. Bull.*, **49**, 626—628 (2001).
- 10) Zhao J., Yang X. W., *J. Asian Nat. Prod. Res.*, **5**, 197—203 (2003).
- 11) Wei F., Ma L. Y., Jin W. T., Ma S. C., Han G. Z., Khan I. A., Lin R. C., *Chem. Pharm. Bull.*, **52**, 1246—1248 (2004).
- 12) Sakurai T., Nishimura T., Otake N., Yao X. S., Abe K., Zeida M., Nagasawa H., Sakuda S., *Bioorg. Med. Chem. Lett.*, **12**, 807—810 (2002).
- 13) Liu H. W., Xiong Z. L., Li F. M., Qu G. X., Kobayashi H., Yao X. S., *Chem. Pharm. Bull.*, **51**, 1089—1091 (2003).
- 14) Perry M. B., Hulyalkar R. K., *Can. J. Biochem.*, **43**, 573—579 (1965).
- 15) Chen Y. J., Takeda T., Ogihara Y., *Chem. Pharm. Bull.*, **51**, 1387—1394 (1985).
- 16) Hu K., Dong A. J., Yao X. S., Kobayashi H., Iwasaki S., *Planta Med.*, **62**, 573—575 (1996).
- 17) Wang S. L., Cai B., Cui C. B., Liu H. W., Wu C. F., Yao X. S., *J. Asian Nat. Prod. Res.*, **6**, 115—125 (2004).